GORE髂动脉分支内假体在临床试验与真实世界注册登记中的结局
报告GORE髂动脉分支内假体(IBE)在美国IDE试验中的中期结局,并与GREAT全球注册登记中真实世界人群的6个月结局比较。IDE试验纳入99例,GREAT登记纳入92例;IBE联合髂总动脉瘤修复安全有效,血栓事件少见且集中于术后1个月内,通常可经血管内再干预解决。
要点
- GREAT登记患者较IDE试验年龄更大、身高更矮、体重更低,女性比例更高(8% vs 1%,P=.02)。
- IDE试验12个月和24个月髂内分支通畅率均为93.6%(95%CI 86.4%-97.1%)。
- IDE试验24个月时8.7%患者腹主动脉瘤囊扩张、21.7%囊回缩;髂总动脉瘤囊无扩张、45%回缩。
核心结论
- IDE试验中期结局与GREAT登记6个月结局提示,使用IBE装置行血管内主动脉瘤修复联合髂总动脉瘤修复安全有效。
- 血栓事件不常见且集中于指数术后第1个月,通常可通过血管内再干预解决。
研究设计与样本
- 美国IDE试验:2013年至2016年纳入99例因髂总动脉瘤或主髂动脉瘤接受IBE治疗的患者,双侧IBE仅允许在持续准入阶段使用。
- GREAT全球注册登记:2013年至2016年纳入92例接受IBE治疗的患者。
- 比较IDE试验与GREAT登记的基线特征、手术变量及6个月内再干预;IDE试验通过2年评估临床和核心实验室判读的影像结局。
主要发现
- GREAT患者显著年龄更大(P=.01)、身高更矮(P<.001)、体重更低(P<.001);GREAT女性显著多于IDE试验(8% vs 1%;P=.02)。
- GREAT有13例(14%)行双侧IBE,IDE持续准入阶段35例中4例(11%)行双侧IBE(P=.70)。
- IDE患者更常采用经皮入路(55% vs 40%;P=.04)。
- IDE试验3例、GREAT登记3例在1个月时接受再干预,其中IDE 2例(2.1%)、GREAT 1例(1.6%)因血栓事件再干预;两组各另有5例在6个月内因非血栓事件再干预(5% vs 5%;P=.92)。
- IDE试验12个月和24个月髂内分支通畅率均为93.6%(95%CI 86.4%-97.1%)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We report midterm outcomes with the GORE Iliac Branch Endoprosthesis (IBE; W. L. Gore & Associates, Flagstaff, Ariz) in the U.S. investigational device exemption (IDE) trial and comparatively assess outcomes in the IDE trial with outcomes in a real-world population of patients treated in the Gore Global Registry for Endovascular Aortic Treatment (GREAT). METHODS: From 2013 to 2016, the IDE trial enrolled 99 patients treated with the IBE for common iliac artery (CIA) aneurysms or aortoiliac aneurysms. Bilateral IBE treatment was allowed only in the continued access phase. From 2013 to 2016, there were 92 patients treated with the IBE in the GREAT registry. Baseline characteristics, procedural variables, and reinterventions through 6 months were compared in the IDE trial and GREAT registry. Clinical and core laboratory-assessed imaging outcomes were assessed in the IDE trial through 2 years. RESULTS: GREAT patients were significantly older (P = .01) and of shorter height (P < .001) and lower weight (P < .001). There were also significantly more women treated in GREAT vs the IDE trial (8% vs 1%; P = .02). Thirteen GREAT patients (14%) and 4 of 35 continued access IDE patients (11%) had bilateral IBE placement (P = .70). IDE patients were more likely to be treated with percutaneous access methods (55% vs 40%; P = .04). Three IDE patients and three GREAT patients underwent 1-month reintervention, with two IDE reinterventions (2.1%) and one GREAT reintervention (1.6%) for thrombotic events. Five additional patients in each study underwent reintervention through 6 months (5% vs 5%; P = .92), all for nonthrombotic events. Internal iliac limb patency was 93.6% (95% confidence interval, 86.4%-97.1%) at 12 and 24 months in the IDE study. Subset analyses of the 10 IDE and GREAT patients with ≤6-month reintervention vs 181 intervention-free patients found that acute myocardial infarction (P = .01), nonpercutaneous access (P = .01), and surgical conduit use (P < .001) were associated with reintervention through 6 months. In the IDE trial, 3.4% and 4.1% of patients underwent reintervention at 12 months and 24 months, respectively, all for treatment of type II endoleaks. At 24 months, 8.7% of IDE patients exhibited abdominal aortic aneurysm sac expansion; 21.7% exhibited abdominal aortic aneurysm sac regression. No patients exhibited CIA aneurysm sac expansion; 45% exhibited CIA aneurysm sac regression. CONCLUSIONS: Midterm IDE outcomes and 6-month outcomes in the worldwide GREAT registry suggest that endovascular aortic aneurysm repair with concomitant CIA aneurysm repair with the IBE device is safe and effective. Thrombotic events are uncommon and are concentrated in the first month after the index procedure, and they typically can be resolved with endovascular reintervention.
引用
- Schneider DB, Milner R, Heyligers JMM, et al. Outcomes of the GORE Iliac Branch Endoprosthesis in clinical trial and real-world registry settings. J Vasc Surg. 2018. PMID: 30064841. doi:10.1016/j.jvs.2018.05.200
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。